Stock DC4 DEXCOM, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings DexCom, Inc. Berne S.E.

Equities

DC4

US2521311074

End-of-day quote Berne S.E.
Other stock markets
 06:00:00 2024-06-19 pm EDT 		5-day change 1st Jan Change
102.4 CHF -13.33% Intraday chart for DexCom, Inc. -.--% -.--%
Jul. 15 Morgan Stanley Cuts Price Target on DexCom to $120 From $132, Keeps Equalweight Rating MT
Jul. 12 Stifel Adjusts Price Target on DexCom to $132 From $145 MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's high margin levels account for strong profits.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 64.25 times its estimated earnings per share for the ongoing year.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
DEXCOM, INC. Stock DexCom, Inc.
-.--% 46.16B -
ABBOTT LABORATORIES Stock Abbott Laboratories
-6.68% 179B
C+
MEDTRONIC PLC Stock Medtronic plc
-5.20% 100B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.38% 66.67B
A
HOYA CORPORATION Stock Hoya Corporation
+17.99% 44.81B
B+
CENCORA, INC. Stock Cencora, Inc.
+9.74% 44.38B
B-
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+14.01% 29.53B
B
TERUMO CORPORATION Stock Terumo Corporation
+21.59% 25.83B
A-
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-6.53% 23.97B
A-
ZIMMER BIOMET HOLDINGS, INC. Stock Zimmer Biomet Holdings, Inc.
-11.70% 22.11B
B
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. DXCM Stock
  4. DC4 Stock
  5. Ratings DexCom, Inc.